<DOC>
	<DOCNO>NCT02244710</DOCNO>
	<brief_summary>Randomized clinical trial assess influence treatment ticagrelor clopidogrel number CECs ( Circulating Endothelial Cells ) EPCs ( Endothelial Progenitor Cells ) patient ACS ( Acute Coronary Syndrome ) , baseline level chronic level ( 1 month ) .</brief_summary>
	<brief_title>EndoTic - Endothelium Ticagrelor</brief_title>
	<detailed_description>ACS Patients treatment group assess : Baseline , 48h 1 month cell count do CECs EPCs Platelet Function 48h 1month Adverse Events , ECG blood test result also collect</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Willing sign Informed Consent Form 18 yr old Male female ( post menopause contraception treatment ) ACS diagnose elevation myocardial infarction biomarkers ( 3rd Universal Definition MI ) Planned invasive strategy ( coronariography perform within 72hrs admission ) Aspirin , clopidogrel ticagrelor allergy . Hemorrhagic diathesis high risk bleeding . Current treatment oral anticoagulant , thienopyridines ticagrelor . Limited life expectancy . Elective surgery plan . High chance able complete followup period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Circulating Endothelial Cells</keyword>
	<keyword>Endothelial Progenitor Cells</keyword>
	<keyword>Acute coronary syndrome ( ACS )</keyword>
	<keyword>Ticagrelor</keyword>
</DOC>